Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature

BACKGROUND: Erythropoiesis-stimulating agents (ESAs) have revolutionized the therapeutic strategy for anemia in chronic kidney disease. However, some cases are resistant or hyporesponsive to ESAs. Roxadustat is an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor that stimulates erythropoie...

Descripción completa

Detalles Bibliográficos
Autores principales: Fei, Min, Wen, Xiang-Qiong, Yu, Zhao-Lan, Kang, Ting, Wu, Wei-Hua, Ou, San-Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130086/
https://www.ncbi.nlm.nih.gov/pubmed/34046470
http://dx.doi.org/10.12998/wjcc.v9.i15.3680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130086/
https://www.ncbi.nlm.nih.gov/pubmed/34046470
http://dx.doi.org/10.12998/wjcc.v9.i15.3680

Ejemplares similares